PHILADELPHIA, Feb. 20 /PRNewswire/ -- According to Anapol Schwartz (http://www.anapolschwartz.com/) attorney James Ronca (http://www.anapolschwartz.com/attorneys/jim_ronca.shtml), a New England Journal of Medicine study (http://content.nejm.org/cgi/content/short/358/8/771?query=TOC) (to be released in the February 21, 2008, print edition) confirms that Bayer AG's blood-clotting drug Trasylol(R), used in coronary artery bypass graft (CABG) procedures, causes kidney/renal failure and increases mortality risk. While initial findings of the study, commissioned by Bayer, were sent to the drug company and the FDA in 2006, this is the first time the final results have been published in full.
Ronca, who is one of the chairs of the national Trasylol(R) litigation, and represents a dozen families and victims (see Trasylol(R) lawsuit (http://www.anapolschwartz.com/practices/trasylol/) and a recent wrongful death complaint (http://www.anapolschwartz.com/practices/trasylol/thompson-complaint.pdf) filed in Philadelphia), argues this study reinforces inherent problems in the FDA's screening process and opens the floodgates for additional litigation.
"According to published sources, thousands may have died from Trasylol(R), when this could have been prevented. Again, we have another example of the FDA not protecting the public -- and the safety of individuals taking a back seat to company profits," says Ronca, who leads advocacy initiatives to raise awareness about Trasylol's(R) side effects.
Pulled by Bayer from the market in November 2007 in response to FDA concerns, Trasylol(R) is administered by an anesthesiologist during CABG surgery (http://www.anapolschwartz.com/practices/trasylol/thompson-complaint.pdf) to limit bleeding. Affected patients typically experience kidney/renal failure symptoms within 48 hours. Many, however, are unaware they have received the drug, complicating diagnosis.
"These findings should further educate the public about Trasylol's(R) dangers, and open the door for victims, and those who don't realize they are victims, to receive remuneration for their injuries," stresses Ronca, who has served as counsel to victims in product liability cases involving Baycol, LOTRONEX, hormone replacement therapy and breast implants.
Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley is a personal injury
firm with law offices in Philadelphia, Reading, Media, and Harrisburg, Pa.,
as well as Cherry Hill, N.J.
(http://www.anapolschwartz.com/contactus.shtml) The firm is a multi-faceted
practice with a tradition of excellence in medical malpractice law,
pharmaceutical mass tort, toxic tort, class actions, products liability,
automobile, securities and wrongful termination litigation. Since its
founding in 1977, the firm has grown to over 30 attorneys, and compiled a
record of success exceptional among its peers.
Contact: Alexandra Kane-Weiss/Jennifer Wasilisin
|SOURCE Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley|
Copyright©2008 PR Newswire.
All rights reserved